feed,title,long_url,short_url
Benzinga,Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab,https://benzinga.com/general/biotech/23/11/36021328/tiziana-expects-to-start-enrolling-patients-in-its-phase-2-clinical-trial-to-treat-secondary-prog,https://da.gd/pccuBW
